Premium
Thrombolytic Therapy with Tissue Plasminogen Activator for the Treatment of Nonstructural Malfunction of Bileaflet Cardiac Valve Prostheses
Author(s) -
Teshima Hideki,
Hayashida Nobuhiko,
Nishimi Masaru,
Tayama Eiki,
Fukunaga Shuji,
Tomoeda Hiroshi,
Chihara Shingo,
Enomoto Naofumi,
Kawara Takemi,
Aoyagi Shigeaki
Publication year - 2002
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1046/j.1525-1594.2002.06988.x
Subject(s) - medicine , complication , tissue plasminogen activator , surgery , cardiology , t plasminogen activator , cardiac valve , plasminogen activator , thrombolysis , cardiac surgery , myocardial infarction
This study was conducted to determine the effect of thrombolytic therapy with tissue plasminogen activator (t‐PA) for nonstructural malfunction of bileaflet cardiac valve prostheses. Twenty‐seven patients with bileaflet prosthetic valve malfunction diagnosed by a combination of cineradiography and transthoracic echocardiography were treated with the administration of intravenous t‐PA. The treatment resulted in complete success in 55.6% (15 of 27), partial success in 22.2% (6 of 27), and no change in 22.2% (6 of 27). In the complete success and partial success groups, the condition of the patients in 85.7% (18 of 21) of the cases improved within 24 h after the administration of t‐PA. Six cases in whom thrombolytic therapy was instituted more than 1 month (ranged from 1 to 38 months, mean 14.7 months) after the diagnosis of prosthetic valve malfunction showed significantly less effectiveness of thrombolytic therapy with t‐PA. Only one patient (3.7%) had a major complication (thromboembolism) after t‐PA treatment. The results suggest that thrombolytic therapy with t‐PA in patients with nonstructural malfunction of bileaflet cardiac valve prostheses is effective with low incidence of complication when the treatment is instituted early after the diagnosis.